PPT-Raltegravir plus Ritonavir-Boosted Darunavir NEAT001/ANRS 143 Trial

NEAT001ANRS 143 Trial Darunavirr Raltegravir versus Darunavirr TDFFTC NEAT001ANRS143 Study Design Source Raffi F et al Lancet 2014384194251 Darunavir Ritonavir QD Raltegravir BID . Heiner C. Bucher for the Opportunistic Infections working group of COHERE in EuroCoord. 2. Background. More than 90% of patients can achieve full suppression within a year of starting modern cART. Information on prognosis in these patients in relation to CD4 cell recovery is therefore important. at the start of antiretroviral therapy in low-, middle- and high-income countries. Nanina Anderegg. , Ole Kirk. for the IeDEA & COHERE consortia. 24.07.2017. 1. c. onflict of interest . 2. N. o. research. site, Abidjan, Côte d’Ivoire. 2 : INSERM U897, Université de Bordeaux, France. 3 : . CeDReS. , CHU Treichville, Abidjan, Côte d’Ivoire. 4 : Service des Maladies Infectieuses et Tropicale, CHU de Treichville, Abidjan, Côte d’Ivoire. Learning Objectives. EARLY VS DEFERRED ART. The Case is Made. Should Early-Stage Asymptomatic HIV Patients Receive ART? . The INSIGHT START Study. The CD4 Cell Count As a Measure . of Immune Deficiency in HIV Patients. PROTEA Trial. Darunavir/r . M. onotherapy. versus Triple Therapy . PROTEA. : Study Design. Source: . Antinori. A, et al. . J Int AIDS Soc. 2014;17:19525.. Darunavir 800 mg QD. + Ritonavir 100 mg . QD. DUAL-GESIDA. Dual Maintenance ART with RTV-Boosted Darunavir + . Lamivudine. DUAL . GESIDA: . Study Design. Source: . Pulido. . F, . et al. . Clin Infect . Dis..  . 2017;65:2112-8.. DRV + RTV + 3TC. Lopinavir. -RTV in Treatment Experienced. TITAN Trial. Darunavir/. r . versus Lopinavir/r in Treatment-Experienced . TITAN. : Study Design. Source: . Madruga. JV, et al. Lancet. 2007;370:49-58. . Darunavir. FLAMINGO. Dolutegravir + 2 NRTIs versus Darunavir + RTV + 2 NRTIs . FLAMINGO: Study Design. Source: . Clotet. B, et al. . Lancet. 2014;383:2222-31. . Dolutegravir + . TDF-FTC or ABC-3TC. (n = 242). Darunavir + Ritonavir + . SPRING-2 Study. Dolutegravir. versus Raltegravir. SPRING-2: Design. Source: . Raffi. F, et al. Lancet. 2013;381:735-43.. Dolutegravir. : 50 mg QD. Fixed-dose NRTI backbone*. (n = 411). Raltegravir. POTENT Trial. Tipranavir. /. r . versus Darunavir. /r . in Treatment-Experienced . POTENT. : Study Design. Source: . Elgadi. MM, et al. . Drugs R D. . 2011;11:. 295-. 302.. Tipranavir. . + . R. itonavir BID . R. itonavir to Raltegravir. SWITCHMRK 1 & 2 Trials. Switching from Lopinavir-Ritonavir to Raltegravir. SWITCHMRK 1 & 2 Trials: Study Design. Source: . Eron. JJ, et al. Lancet. 2010;375:396-407.. DRIVE FORWARD. Doravirine. + 2 NRTIs vs. Darunavir + Ritonavir + 2 NRTIs. DRIVE FORWARD: Design. Source: Molina J-M, et al. Lancet HIV. 2018;5:e211-20.. Doravirine. + 2 NRTIs. (n = 385). Darunavir + RTV + 2 NRTIs. POWER 1 and 2. Darunavir. /. r versus other PIs in Treatment-Experienced . POWER 1 and 2. : Study Design. Source: . Clotet. B, et al. . Lancet. . 2007;369:. 1169-78.. Darunavir BID + RTV BID + OBR . RADAR Trial. Raltegravir. + Darunavir/r versus TDF-FTC + Darunavir/r. RADAR: Study Design. Source: . Bedimo. RJ, et al. . PLoS. One. 2014;9:e106221.. Darunavir QD + Ritonavir QD + Raltegravir BID .